

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101015736


The EU-RESPONSE trials

EU workshop on broad-spectrum antivirals Marius Trøseid, on behalf of EU RESPONSE





How to avoid the research chaos of 2020?



Top Drugs Based on Enrollment Count and Study Numbers



•••


If we had access to broad spectrum antivirals from the start...

- How to test efficacy of drugs fast enough?
- How to test safety of drugs detailed enough?
- How to test the right drug for the right population?
- How to update knowledge when the virus and patient population evolve during the pandemic?










COVID-19 clinical trials: learning from exceptions in the research chaos


Of the >2,000 planned drug studies examining COVID-19 treatments (https:// www.covid-trials.org), most have delivered little or no directly useful information¹.

NATURE MEDICINE | www.nature.com/naturemedicine



Solidarity, N Engl J Med 2020


....



COVID-19 clinical trials: learning from exceptions in the research chaos

Of the >2,000 planned drug studies examining COVID-19 treatments (https:// www.covid-trials.org), most have delivered little or no directly useful information¹.

NATURE MEDICINE | www.nature.com/naturemedicine



Solidarity, N Engl J Med 2020

RESPONSE							
0		à	21 Partners	(E)	16 Countries		
١	WP		Title				
	1		Extending Discovery in Europe				

	Inserm	
Extending Discovery in Europe	Université Libre de Bruxelles	
	Centro Hospitalar Sao Joao	
	Oslo University Hospital	
EU-SolidAct	Inserm	
	Universita degli Studi di Verona	
Coordination of the European COVID 10 Adaptive Distance trials	ECRIN	
Coordination of the European COVID-19 Adaptive Platform trials	Norwegian Institute of Public Health	
Project management, coordination, communication and	Inserm	
dissemination	Inserm Transfert	





Lead








Creating a platform trial for future pandemics

- Pragmatic enough to enable patient inclusion across Europe
- Granular safety data for EMA approval
- Flexible data capture related to local resources
 Biobanking in sites with capacity and experience
- Remote follow-up after discharge









Creating a platform trial for future pandemics

Testing different drugs for different disease states








8

Trial coordination and shared resources







Completed and ongoing* trials

	Population	Intervention	Main outcome
NOR-Solidarity	Moderate, severe	Remdesivir	Viral clearance
DicCoVeRy I	Moderate, severe	Remdesivir	Clinical status day 15
DicCoVeRy II	Moderate	Evusheld	Clinical status Day 15
Bari-SolidAct	Severe, critical	Baricitinib	Mortality Day 60
AXL-SolidAct*	Moderate	Bemcentinib	Disease state Day 8










EU RESPONSE trials and remdesivir



Barratt-Due et al, Ann Int Med 2021




- Antiviral drug, but no documented effect on viral load in nasopharynx
- Other modes of action?
- Need for individual level meta analysis (paper submitted)

Trøseid et al, Lancet Inf Dis 2021



Baricitinib: Different safety profile in vaccinated?




Significant interaction between vaccination and serious adverse events Vaccinated were older with more comorbidities and less inflammation: inadequate immune response to vaccines?

EU SolidAct, Critical Care 2022



Are data from immunologically naive patients pre-Omicron still relevant?

Pre-omicron/unvaccinated










Are data from immunologically naive patients pre-Omicron still relevant?

Omicron/vaccinated/immunocompromised









Are data from immunologically naive patients pre-Omicron still relevant?

Immunocompromised patients have been neglected in COVID-19 trials: a call for action

Marius Trøseid ^{1, *}, Maxime Hentzien ², Florence Ader ³, Sandra Wagner Cardoso ⁴, Jose R. Arribas ⁵, Jean-Michel Molina ⁶, Nicolas Mueller ⁷, Maya Hites ⁸, Fabrice Bonnet ⁹, Oriol Manuel ¹⁰, Dominique Costagliola ¹¹, Beatriz Grinsztejn ⁴, Inge Christoffer Olsen ¹², Yazdan Yazdapanah ¹³, Alexandra Calmy ², On behalf of EU RESPONSE, COMBINE Table 1



Proportion of immunocompromised participants in registration trials of antiviral drugs

	Drug	Remdesivir	Nirmatrelvir/ritonavir	Sotrovimab
	Primary end point Population	Hospitalization or death within 28 days Symptoms \leq 7 days, at least one risk factor	Hospitalization or death within 28 days Symptoms <5 days, high risk patients	Hospitalization or death within 29 days Symptoms <5 days, at least one risk factor
Γ	Immuno-compromized, %	5	<1	Excluded
	Efficacy data, n (%)	2/279 (0.7) (remdesivir); 15/283 (5.3) (placebo); p = 0.008; RRR = 87%	3/389 (0.8) (nirmatrelvir); 27/385 (7.0) (placebo); p < 0.0001; RRR = 89%	3/291 (1) (sotrovimab); 21/292 (7) (placebo); p = 0.002; RRR = 85%
	Publication	Gottlieb et al. [4]	Hammond et al. [5]	Gupta et al. [6]

RRR, relative risk reduction.



Plans ahead

- Use biobanked material to improve knowledge on safety profile, mode of action of drugs and interaction with host immunity
- Use the network and infrastructure for other emerging infectious diseases, collaboration with other networks on Monkeypox
- Keep the network alive in «peacetime»





If we had access to broad spectrum antivirals we would still need...

- to test drugs in relevant populations
- platform trials that allow rapid inclusion, yet detailed enough regarding safety data
- to include fragile groups of patients from the start
- trial coordination rather than trial competition







Acknowledgements

- Patients
- Site staff
- Investigators
- International Sponsor team
- EMA and regulators
- EU RESPONSE partners
- European Commission





The EU-RESPONSE project has received funding from the European Union's Horizon 2020 Research and Innovation programme, under the Grant Agreement number 101015736

